Hepatic steatosis is the medical term for excess fat stored inside liver cells, and it is the most common chronic liver condition worldwide, affecting roughly 20 to 30 percent of adults in Western countries.1PubMed Central. Non-alcoholic fatty liver disease If you have seen this phrase on an ultrasound report or lab workup, it means your liver is holding on to more fat than it should. The condition sits at the beginning of a spectrum that can, in some people, progress to inflammation, scarring, and serious liver damage, but for most people it is reversible with the right changes.
What Is Happening Inside the Liver
Your liver normally contains a small amount of fat. Under healthy conditions, the organ keeps its fat levels steady by balancing how much fat it takes in and manufactures against how much it burns for energy or ships out into the bloodstream.2PubMed Central. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease Hepatic steatosis develops when that balance tips: too many fatty acids flowing in, too much new fat being built inside liver cells, or too little fat being burned or exported. When any combination of those pathways gets out of proportion, fat droplets accumulate inside the hepatocytes and the liver literally becomes “fatty.”
One process that accelerates in fatty liver is the liver’s internal fat-manufacturing system. Research shows that this pathway ramps up substantially as the disease takes hold, making steatosis worse over time.3PubMed Central. In-depth analysis of de novo lipogenesis in non-alcoholic fatty liver disease: Mechanism and pharmacological interventions The liver also tries to compensate by burning more fat, but that compensatory effort often falls short and can itself generate harmful byproducts that damage cells, especially when mitochondria are already stressed.4PubMed Central. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Why the Name Keeps Changing
For decades, the standard term was non-alcoholic fatty liver disease, or NAFLD. That label defined the condition by what it was not: it was not caused by alcohol. In recent years, liver specialists moved away from that name and adopted metabolic dysfunction-associated steatotic liver disease, or MASLD. The switch reflects a shift toward describing what is causing the fat buildup rather than simply ruling out alcohol.5PubMed Central. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease Under the new framework, a diagnosis of MASLD requires evidence of liver fat plus at least one metabolic risk factor such as excess weight, high blood sugar, high blood pressure, or abnormal cholesterol. A middle category called MetALD covers people who have metabolic risk factors and also drink more than modest amounts of alcohol.
You will still see “NAFLD” in many lab reports, older guidelines, and published research. The terms refer to largely the same population of patients, so if your doctor says one or the other, they are talking about the same core problem: metabolic fat accumulation in the liver.
Where Alcohol Fits In
Alcohol-related fatty liver has always been recognized as its own entity. Under current criteria, the threshold for “significant” alcohol intake is roughly 20 to 50 grams per day for women and 30 to 60 grams per day for men.6Journal of Obesity & Metabolic Syndrome. Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index for Classification of Patients with Steatotic Liver Disease To put that in perspective, a standard drink in the United States contains about 14 grams of alcohol, so the boundary sits at roughly one to three drinks per day depending on sex. People who drink below those thresholds and have metabolic risk factors fall into the MASLD category, while those who drink above the upper limit are classified as having alcohol-associated liver disease. The MetALD group sits in between, where both metabolic factors and moderate-to-heavy drinking contribute.
Insulin Resistance as a Central Driver
If there is a single metabolic thread connecting most cases of fatty liver, it is insulin resistance. When fat tissue becomes resistant to insulin, it releases more fatty acids into the bloodstream. Those extra fatty acids flood the liver, and the resulting high insulin levels push the liver to manufacture even more fat internally.7The Journal of Clinical Endocrinology & Metabolism. The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease The cycle feeds itself: excess fat in the liver worsens insulin resistance throughout the body, and worsened insulin resistance drives more fat into the liver.8PubMed. Free fatty acids and insulin resistance This is why fatty liver so often travels with type 2 diabetes, obesity, and metabolic syndrome. Treating one usually helps the others.
Genetics and Individual Susceptibility
Not everyone with the same diet and body weight develops fatty liver. Genetics explains a meaningful chunk of that variation. The most extensively studied gene variant is a change in the PNPLA3 gene. People who carry two copies of the risk version have roughly 73 percent more fat in their livers than people with no copies, along with about a threefold higher risk of inflammation and fibrosis.9PubMed. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease The variant is most common in people of Hispanic descent, which partly explains higher rates of fatty liver in that population, while a different PNPLA3 variant found more frequently in people of African descent is linked to lower liver fat.10PubMed Central. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Beyond simply raising fat content, the PNPLA3 risk variant also predisposes carriers to fibrosis, cirrhosis, and liver cancer over the long term.11PubMed Central. PNPLA3 I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells
Knowing your genetic risk is not yet part of routine clinical practice, but it helps explain why some lean individuals develop fatty liver and why others with significant obesity never do. If fatty liver runs in your family, you may carry variants that lower your threshold for developing it.
Why You Probably Did Not Notice Any Symptoms
Most people with hepatic steatosis feel perfectly fine. The liver does not have pain-sensing nerves inside its tissue, so fat can accumulate silently for years. The majority of cases are discovered incidentally when a doctor orders blood work or an imaging study for an unrelated reason.1PubMed Central. Non-alcoholic fatty liver disease Some people do develop vague fatigue or a dull ache in the upper right abdomen as the liver enlarges, but these symptoms are nonspecific and easy to attribute to other causes. The silent nature of the disease is one of its biggest risks: by the time symptoms are obvious, the liver may already have progressed to more advanced stages.
How Fatty Liver Is Diagnosed and Staged
A standard abdominal ultrasound can detect moderate-to-severe fat in the liver and is usually the first tool used. It is cheap, widely available, and radiation-free, but it struggles with mild steatosis and cannot easily quantify exactly how much fat is present. For precise fat measurement, MRI-based proton density fat fraction is the current gold standard for imaging. It correlates strongly with biopsy findings and is the most accurate non-invasive way to quantify liver fat.12PubMed Central. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging Studies have shown it can distinguish between the presence and absence of steatosis with extremely high accuracy.13PubMed Central. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH Newer ultrasound-based attenuation techniques are also showing strong performance and may eventually bring MRI-level precision to a more accessible platform.14PubMed Central. Accuracy of attenuation coefficient measurement (ACM) for hepatic steatosis: comparison with MRI proton density fat fraction (MRI-PDFF) and chemical fat analysis using multimodal liver fat phantoms
Once steatosis is confirmed, the next critical question is whether the liver has developed fibrosis, or scarring. Doctors often start with simple blood-test-based scoring tools like FIB-4 and the NAFLD Fibrosis Score. These calculations use routine lab values combined with age and body measurements and are especially good at ruling out significant fibrosis, which avoids the need for more invasive testing in many patients.15PubMed Central. Comparing the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score with transient elastography scores of people with non-alcoholic fatty liver disease When scores land in an uncertain range, elastography, a specialized ultrasound or MRI technique that measures liver stiffness, can provide a more detailed answer. Studies comparing different elastography methods have found similar accuracy for detecting various stages of fibrosis.16PubMed Central. Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD Liver biopsy remains the definitive way to grade and stage the disease, but because it is invasive and carries a small risk of complications, it is typically reserved for cases where non-invasive tests are inconclusive or a clinical decision hinges on the exact histological picture.
The Progression Spectrum
Hepatic steatosis on its own is considered the mildest form of the disease. The concern is what comes next. In some people, fat accumulation triggers ongoing inflammation and cell injury, a stage called steatohepatitis, characterized by hepatocyte ballooning and chronic inflammation.17PubMed Central. The menopause-obesity axis in MASH progression: from estrogen decline to liver fibrosis From there, the liver can begin laying down scar tissue. Fibrosis is graded on a five-point scale, from no scarring at all through mild portal or peri-sinusoidal fibrosis, to bridging fibrosis, and ultimately cirrhosis, where the liver’s architecture is substantially replaced by scar tissue.18PubMed Central. Predicting Fibrosis Stage in MASH: The Role of Total Metabolic Syndrome Score and MMP-1 Not everyone moves through every stage. Many people with simple steatosis never progress, while others advance to significant fibrosis over years or decades. The speed of progression depends on genetics, ongoing metabolic stress, alcohol intake, and other factors.
The Heart Risk That Surprises People
Liver disease is not the leading cause of death in people with fatty liver. Heart disease is. Cardiovascular risk in patients with fatty liver was roughly 2.6-fold higher than in matched controls in a large study, and life expectancy was on average about 2.8 years shorter, with the biggest impact seen when fatty liver was diagnosed in middle age.19PubMed Central. Risk of cardiovascular disease and loss in life expectancy in NAFLD The association goes beyond the shared metabolic risk factors. There is growing evidence that fatty liver independently raises the risk of high blood pressure, coronary artery disease, heart rhythm problems, and structural heart changes.20PubMed Central. NAFLD and cardiovascular diseases: a clinical review If you are told you have hepatic steatosis, your doctor should be checking your cardiovascular risk profile, not just your liver enzymes.
Diet, Weight Loss, and the Threshold Effect
Lifestyle changes remain the first-line treatment. The evidence on weight loss is surprisingly specific: losing at least 5 percent of your body weight can reduce liver fat, losing 7 percent or more can resolve inflammation, and losing 10 percent or more can start to reverse fibrosis.21Gastroenterology. Lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease (NAFLD) These thresholds give people concrete targets rather than the vague advice to “lose some weight.”
As for what to eat, the Mediterranean diet has emerged as the recommended pattern for people with fatty liver, endorsed by European liver and diabetes societies. It emphasizes olive oil, nuts, fish, fruits, vegetables, and whole grains while limiting red and processed meat, saturated fat, and added sugars, especially commercially produced fructose.22PubMed Central. Nonalcoholic Fatty Liver Disease and Obesity Treatment Fructose deserves a specific mention because it is metabolized almost entirely by the liver and is a potent driver of liver fat synthesis. Cutting back on sugary drinks and heavily processed foods with added fructose can make a meaningful difference even before the scale moves much.
Exercise Even Without Weight Loss
One of the more encouraging findings in this area is that exercise helps the liver even when it does not lead to weight loss. Both aerobic and resistance training reduce liver fat.23PubMed Central. The Effects of Physical Exercise on Fatty Liver Disease In one trial, eight weeks of resistance exercise produced a relative reduction in liver fat of about 13 percent without any change in body weight or total body fat.24PubMed Central. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss Separate research has confirmed that exercise alone, without dietary changes, can improve liver fat and glucose tolerance, again without weight loss.25PubMed Central. Exercise without dietary changes alleviates nonalcoholic fatty liver disease without weight loss benefits This matters because many people feel discouraged when the number on the scale does not budge. If you are exercising regularly and not losing weight, your liver may still be benefiting substantially.
Medications on the Horizon and Already Here
Until recently, there were no approved drugs specifically for fatty liver disease. That changed in 2024 with the approval of resmetirom, an oral medication that targets a thyroid hormone receptor in liver cells.26PubMed Central. Resmetirom and thyroid hormone receptor-targeted treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) It is approved for adults with steatohepatitis and moderate-to-severe fibrosis who do not yet have cirrhosis. By activating this receptor, resmetirom promotes fat burning in the liver, improves mitochondrial function, and tamps down the liver’s internal fat-production machinery.27PubMed Central. A new liver-targeted agonist of thyroid hormone receptor beta resmetirom in treating MASLD/MASH: From mechanism to therapy In the pivotal trial, roughly a quarter to 30 percent of patients on resmetirom achieved resolution of steatohepatitis with no worsening of fibrosis, compared to about 10 percent on placebo. A similar share saw fibrosis improve by at least one stage. Resmetirom also lowered LDL cholesterol by about 14 to 16 percent, a useful bonus given the cardiovascular risk discussed earlier.28PubMed. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Another drug class drawing attention is GLP-1 receptor agonists, originally developed for diabetes and now widely used for weight management. These medications have shown improvements in liver fat, liver enzyme levels, and histological markers of fatty liver and fibrosis.29PubMed Central. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives Newer dual-agonist compounds that target both the GLP-1 and glucagon receptors are being tested in animal models and early trials, with some showing liver benefits beyond what current single-target drugs achieve.30Diabetes. 2156-LB: Superior Hepatoprotective Effects of OPK-88006, a Novel GLP-1/Glucagon Receptor Dual Agonist, to Semaglutide and Survodutide in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH None of the GLP-1 drugs have a formal fatty-liver-specific indication yet, but many doctors prescribe them for patients who have both diabetes or obesity and fatty liver.
When Surgery Enters the Picture
For people with severe obesity who have not responded to other approaches, bariatric surgery can produce dramatic improvements in liver disease. In one retrospective cohort, more than three quarters of patients achieved complete resolution of steatohepatitis after metabolic surgery, and all patients who had fibrosis at baseline saw it resolve entirely.31PubMed Central. Impact of metabolic and bariatric surgery on MASLD: histological resolution and metabolic outcomes in a retrospective cohort These results are remarkable, though the study was small and retrospective, so the numbers should be interpreted with caution. The broader body of evidence supports bariatric surgery as one of the most effective interventions for fatty liver in the right candidates, largely because the weight loss it produces far exceeds what most people sustain through diet and exercise alone.
Less Obvious Contributors
Beyond diet, weight, and alcohol, several underappreciated factors can influence fatty liver. Sleep is one. Short sleep, poor sleep quality, disrupted circadian rhythms, and conditions like obstructive sleep apnea have all been linked to both the onset and progression of fatty liver. Disrupted sleep patterns can impair how the body handles fat and insulin and may amplify inflammatory stress in liver cells.32Nature Index. Sleep Patterns and Non-Alcoholic Fatty Liver Disease
Environmental chemicals are another less familiar contributor. Endocrine-disrupting chemicals, a broad category that includes certain pesticides, plasticizers, and industrial compounds, have been linked to fatty liver in both human observational studies and animal experiments.33PubMed Central. Endocrine-disrupting chemicals and fatty liver disease These chemicals can interfere with hormone receptors and alter gene expression in ways that promote fat accumulation.34PubMed Central. RISING STARS: Sex differences in toxicant-associated fatty liver disease This research is still evolving and does not yet translate into specific personal recommendations beyond the general advice to minimize unnecessary chemical exposures, but it reinforces that fatty liver is not purely a matter of willpower and diet.
The Gut Connection
The liver receives blood directly from the intestines through the portal vein, so it is exposed to everything the gut absorbs, including bacterial products. When the balance of gut bacteria is disrupted, the intestinal wall can become more permeable, allowing bacterial toxins to reach the liver in greater quantities. These toxins activate immune cells within the liver, triggering inflammation that can push simple steatosis toward steatohepatitis and fibrosis.35PubMed Central. Fatty Liver Disease and Gut Microbiota: A Comprehensive Update Research into whether probiotics or targeted microbiome therapies can help treat fatty liver is ongoing, with some early results looking promising but nothing definitive enough to recommend specific supplements yet. For now, the practical takeaway is that gut health and liver health are deeply intertwined, and a fiber-rich diet that supports a diverse microbiome is likely working in your liver’s favor too.